• Logout
HCP SMA News Today
  • e-Newsletter
  • Home
  • HCP Specialties
    • Genetic Counselors
    • Orthopedics
    • Pulmonologists
    • Nursing
    • Neurologists
    • Social Workers
    • Physical Therapists
    • Nutritionists
    • Radiologists
    • Pediatricians
    • Urologists
  • Core SMA Topics
  • About
Select Page

MicroRNAs Can Predict Response to Spinraza, Study Suggests

MicroRNAs Can Predict Response to Spinraza, Study Suggests

by Steve Bryson PhD | May 27, 2022

MicroRNAs isolated from people with spinal muscular atrophy (SMA) types 2 and 3 before treatment predicted eventual responses to Spinraza (nusinersen) therapy, a study suggested. The study, “Muscle microRNAs in the cerebrospinal fluid predict clinical response to...

read more
UK Collaboration Gets £1.25M Grant to Develop ‘Smart Suit’

UK Collaboration Gets £1.25M Grant to Develop ‘Smart Suit’

by Mary Chapman | May 25, 2022

Development of an exoskeleton suit to help those living with progressive neuromuscular conditions that affect their upper-body movement will advance due to a £1.25 million (about $1.5 million) grant from the People’s Postcard Lottery in the United Kingdom. The “SMART...

read more
CADTH Panel Recommends Against Reimbursing Spinraza for Adults

CADTH Panel Recommends Against Reimbursing Spinraza for Adults

by Marisa Wexler MS | May 23, 2022

A committee of the Canadian Agency for Drugs and Technologies in Health (CADTH) has issued a draft recommendation advising Spinraza (nusinersen) should not be reimbursed for the treatment of adults with spinal muscular atrophy (SMA).  CADTH is an independent,...

read more
Evrysdi Safe in Type 1, 2 Patients in US Access Program Before Approval

Evrysdi Safe in Type 1, 2 Patients in US Access Program Before Approval

by Marta Figueiredo PhD | May 20, 2022

Evrysdi (risdiplam) was generally safe and well tolerated in a broader group of children and adults with spinal muscular atrophy (SMA) types 1 and 2 than that included in clinical trials supporting the therapy’s approval. These were the findings of an analysis of...

read more
Using Cupping During Physical Therapy For Patients With SMA

Using Cupping During Physical Therapy For Patients With SMA

by Emily Jones | May 19, 2022

Recently, Michael, our patient with SMA, has exhibited some increased tenderness and reduced tissue mobility to his calf muscles bilaterally. This is no surprise since he doesn’t wear footrests and is constantly in a plantarflexed, or toe-down position. In this...

read more
Zolgensma Safe in Children Heavier Than Those in Trials, Data Show

Zolgensma Safe in Children Heavier Than Those in Trials, Data Show

by Marta Figueiredo PhD | May 18, 2022

Zolgensma appears generally safe and well tolerated among spinal muscular atrophy (SMA) patients weighing 8.5 kilograms (about 18.7 lbs) or more, with no new safety concerns identified in the heavier group. Notably, 8.5 kilograms was the maximum weight of SMA patients...

read more
From Actor to Attorney, Woman’s ‘Work Ethic Outshines My Disability’

From Actor to Attorney, Woman’s ‘Work Ethic Outshines My Disability’

by Hawken Miller | May 16, 2022

From being a child actor to a lawyer in the entertainment industry, Alexa Dectis, who has relied on a power wheelchair to get around since she was 2, has gone far. Dectis, diagnosed with spinal muscular atrophy (SMA) type 2 when she was 18 months old, was named to the...

read more
Spinraza Stabilizes Motor Function for Adults With SMA, Study Reports

Spinraza Stabilizes Motor Function for Adults With SMA, Study Reports

by Marisa Wexler MS | May 13, 2022

Treatment with Spinraza (nusinersen) modestly improved muscle strength and stabilized motor function for adults with spinal muscular atrophy (SMA) types 2 or 3, according to a study from Israel. The study, “Longer-term follow-up of nusinersen efficacy and safety...

read more
New Gene Therapy Shows Potential for Safety, Efficacy in Mouse Model

New Gene Therapy Shows Potential for Safety, Efficacy in Mouse Model

by Lindsey Shapiro PhD | May 11, 2022

A second-generation investigational gene therapy for spinal muscular atrophy (SMA) showed greater safety and efficacy than an earlier version, and it may be more effective than the currently approved gene therapy for SMA, a study in a disease mouse model reported. The...

read more
Parents of SMA Children Put Health as Top Priority at COVID-19’s Onset

Parents of SMA Children Put Health as Top Priority at COVID-19’s Onset

by Marisa Wexler MS | May 9, 2022

For parents, protecting the health and well-being of a child with spinal muscular atrophy (SMA) was a top priority when the COVID-19 pandemic first hit the Netherlands in early 2020, despite the difficulties isolation can bring, an interview study reports. The study,...

read more
Disease Severity May Be Impacted by SMN Protein in Rare SMA Cases

Disease Severity May Be Impacted by SMN Protein in Rare SMA Cases

by Steve Bryson PhD | May 6, 2022

The stability and self-interacting ability of SMN, the protein that is abnormally low in people with spinal muscular atrophy (SMA), may impact disease severity in rare cases, a small study suggested. Based on their findings, the researchers said new treatment...

read more
Type 1 Children on Evrysdi Continue to Hit Milestones After 3 Years

Type 1 Children on Evrysdi Continue to Hit Milestones After 3 Years

by Marisa Wexler MS | May 4, 2022

Children with spinal muscular atrophy (SMA) type 1 who started treatment with Evrysdi (risdiplam) in the first months of life are continuing to gain motor skills after three years of treatment, according to new data from the FIREFISH trial. “These long-term...

read more
« Older Entries
  • Genetic Counselors
  • Orthopedics
  • Pulmonologists
  • Nursing
  • Neurologists
  • Social Workers
  • Physical Therapists
  • Nutritionists
  • Radiologists
  • Pediatricians
  • Urologists
  • Back to the Top →

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • Publishing Team
  • Leadership
  • Our Culture
  • Corrections Policy
  • Careers
  • Contact Us
  • Terms of Service
  • Disable Notifications
  • Advertising Policy
  • Privacy Policy

Disclaimer:

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.